Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone781-674-4400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.78 million
Profitability
Miscellaneous
Employees294
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Agenus (NASDAQ:AGEN) Frequently Asked Questions
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.42. The biotechnology company had revenue of $8.61 million for the quarter, compared to analysts' expectations of $9.03 million. View Agenus' Earnings History.
When is Agenus' next earnings date?
What price target have analysts set for AGEN?
1 equities research analysts have issued twelve-month target prices for Agenus' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Agenus' share price to reach $5.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Agenus.
What is the consensus analysts' recommendation for Agenus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus.
Has Agenus been receiving favorable news coverage?
Headlines about AGEN stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Agenus earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), MeiraGTx (MGTX) and Cellectis (CLLS).
What other stocks do shareholders of Agenus own?
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)
- Dr. Jennifer Buell, Chief Operating Officer
- Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)
- Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)
- Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)
Who are Agenus' major shareholders?
Agenus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Geode Capital Management LLC (0.88%), Northern Trust Corp (0.86%), Oxford Asset Management LLP (0.69%), Wells Fargo & Company MN (0.61%) and Morgan Stanley (0.60%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus.
Which major investors are selling Agenus stock?
AGEN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Oxford Asset Management LLP, California State Teachers Retirement System, Zurcher Kantonalbank Zurich Cantonalbank and HighTower Advisors LLC. View Insider Buying and Selling for Agenus.
Which major investors are buying Agenus stock?
AGEN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Ingalls & Snyder LLC, Geode Capital Management LLC, Charles Schwab Investment Management Inc., Shell Asset Management Co., Northern Trust Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Agenus.
How do I buy shares of Agenus?
Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of AGEN stock can currently be purchased for approximately $2.95.
How big of a company is Agenus?
Agenus has a market capitalization of $396.07 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe.
What is Agenus' official website?
How can I contact Agenus?
Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]
MarketBeat Community Rating for Agenus (NASDAQ AGEN)
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
